This indicated that silymarin could improve the condition of AD by disintegrating the already produced Aβ plaque, and it could also block the synthesis of Aβ by reducing the APP content in the nervous system, through inhibiting the expression of the APP gene and reducing the accumulation of Aβ from the source. Here, APP is linked to Alzheimer disease.